Answers are grounded in this paper and cite their sources.
(See the Major Article by Suzuki et al on pages 1232–9.) Optimizing antimicrobial utilization (AU) is an important patient safety issue and critical to address the global public health crisis of antimicrobial resistance (AMR). Calls for a coordinated approach to antibiotic stewardship (AS) emerged >40 years ago with subsequent evolution [1–4]. In 2014, the Presidential Executive Order “Combating Antibiotic-Resistant Bacteria” called for a comprehensive AS plan, and the Centers for Disease Control and Prevention (CDC) identified 7 “Core Elements” for a successful hospital antibiotic stewardship program (ASP) [5, 6]. Mounting evidence demonstrates that any healthcare setting can implement an ASP to optimize individual patient outcomes, improve the quality of care, and provide critical patient safety processes that may reduce antimicrobial-associated adverse events, length of stay, and AMR development while simultaneously decreasing costs [6–8]. The National Action Plan directed all acute care hospitals to establish ASPs by 2020 and expand AS across the healthcare continuum [9]. Despite calls for AS across the spectrum of care, efforts often remain siloed (eg, inpatient hospital vs ambulatory clinic) and not specifically designed to facilitate AS during transitions of care. The complexity and importance of care decisions during this critical patient safety window are well-known in both general medical care [10] and medication reconciliation [11]. Emerging data show that antibiotics could be completely avoided in 28% of patients without adverse consequences with required infectious disease consultation at time of discharge [12] and that AS-directed pharmacy intervention can reduce both the spectrum and duration of total postdischarge antibiotic therapy and specifically fluoroquinolone (FQ) use [13]. As evidence examining antibiotic “time-outs” accumulates, the concept that frequent assessment is vital to optimizing AU and appropriateness advances [14]. Tamma and colleagues recently elevated a conceptual framework incorporating 4 key “moments” for clinicians regarding antimicrobial prescribing [15]. In this issue of Clinical Infectious Diseases, Hiroyuki Suzuki and coinvestigators now illustrate a major temporal moment for AS: point of hospital discharge. Utilizing the robust Veterans Health Administration (VHA) hospital system and leveraging VHA’s progressive AS systemic improvements and regulations, [16–18], the authors present data on VHA hospitals stratified by inpatient FQ AS strategy to assess the appropriateness and burden of FQ days of therapy (DOTs) after hospital discharge. A major strength of their retrospective approach was the scope of the study, totaling >1.5 million patient-admissions across 122 hospitals demonstrating that >60% of FQ DOTs—to the tune of 1 052 560 DOTs—occurred after discharge, accounting for nearly 30% of all postdischarge antibiotic DOTs. FQ use is common in both the inpatient and outpatient setting, and there are numerous examples of successful FQ reduction strategies, but a major contribution of this study is highlighting this often-overlooked opportunity [19]. The findings presented align with recent data showing that at least 38% of antibiotic DOTs occur after discharge with FQ as one of, if not the, most common class [20–23]. The true burden in this study may be even higher given the exclusion of patients transferring to long-term care facilities (LTCFs). The authors note that patients discharged to LTCF settings likely represented a minority of patients, though 23% of patients discharged to LTCFs did so with antibiotics in a recent study [24]. The combination of FQ DOTs postdischarge use with the finding that >30% of patients had not received FQ during hospitalization demonstrates the complexity of impacting overall FQ use in the absence of an explicitly focused AS discharge program where antibiotic use in general, and FQ use in particular, may avoid scrutiny. Antimicrobial prescribing is subject to specialized problems during discharge medication reconciliation that may increase errors—namely, cultures awaiting finalization and complexities associated with changes in antibiotic class and spectrum [19, 25]. Accumulating data reveal the higher incidence of collateral damage for patients discharged on antibiotics [20, 21, 24]. A driving rationale behind the current study references FQ’s visible risk profile, the subject of numerous black box warnings, and admonition for reserved use. It is encouraging that some headway in FQ reductions temporally related to cautionary guidance has been reported, though ample opportunity remains [26]. This study is not without limitations, many explicitly discussed in the study. How the appropriateness of antibiotic regimens was determined is the most complex. Every attempt was made to standardize this definition based on evidence-based medicine, guidelines, and available microbiologic data, but in the subset of patient records reviewed, nearly one-quarter required 2 trained infectious disease physicians to adjudicate to reach consensus. For those familiar with the nuances of applying guidelines to individual patients, this does not come as a surprise, but demonstrates the inherent challenge of applying appropriateness to individual antibiotic regimens. Acknowledging this difficulty, high rates of inappropriateness were found at discharge (41%), consistent with both inpatient and outpatient antibiotic use, as well as FQ-specific rates [21–23]. The amount of inappropriate use may have been higher given the exclusion of hospitals with baseline Escherichia coli FQ susceptibility rates <75%. The rationale that empiric FQ use should be less in hospitals with low baseline FQ susceptibility seems reasonable, but not established, given that frontline providers may not always be aware of local resistance patterns or incorporate them into antibiotic decisions as recommended. This study was designed to compare the effect of 3 different inpatient FQ AS strategic categories on discharge FQ use. Some of the subgroup analyses may have been underpowered to draw between-group conclusions, which is further complicated by the undetermined variability, degree of implementation, and self-reported nature of these practices that were unable to be verified by audit. A recent study targeting specific diagnoses found that directed inpatient FQ AS may increase FQ initiation at discharge [23], strengthening the argument for AS engagement throughout the process [27]. This study offers several AS discharge opportunities. Most of the inappropriate use suffered from selection error (ie, FQ should not have been prescribed in the first place). This was particularly true in several expected scenarios: chronic obstructive pulmonary disease exacerbations, cystitis, and urologic procedural prophylaxis. The other large category of inappropriate use was excessive duration. Duration has been rightly emphasized as a major contributor to overall inappropriate use, including hospital discharge [28], especially as shorter durations gain acceptance [29]. These observations may offer potential targets to maximize predischarge antibiotic review by targeting specific syndromes or systematic methods to reduce durations as has been shown in community-acquired pneumonia [30]. Perhaps one of the most provocative questions centers on how to surveil and impact inappropriate AU at discharge. As noted, current CDC AU metrics focus on inpatient use, but the study’s charge to define and monitor AU metrics after discharge is worthy of evaluation. AS opportunities at hospital discharge warrant further study to elucidate best practices and strategies as standard protocols and checklists have demonstrated in other general healthcare and AS settings. Successful implementation of AS at this critical transition point will need to leverage and engage frontline providers, staff, pharmacists, case management, nurses, and the entire care team to impact this unmet need, optimize antibiotic use, and improve patient care. Potential conflicts of interest. The author: No reported conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
No takes yet. Share an insight, caveat, or question.
George E. Nelson (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: